Henagliflozin

also known as SHR3824

Small molecule targets SLC5A2 via inhibition

Developed for: type 2 diabetes mellitus · heart failure · obesity disorder · prediabetes syndrome · chronic kidney disease · cognitive impairment with or without cerebellar ataxia · diabetic kidney disease · hypertrophic cardiomyopathy
+5 more
· metabolic dysfunction-associated steatotic liver disease · myocardial infarction · NAFLD1 · atrial fibrillation · kidney failure
Investigated by: Jiangsu HengRui Medicine Co., Ltd. · Shandong Suncadia Medicine Co., Ltd. · Second Affiliated Hospital of Soochow University · Affiliated Hospital of Jiangsu University · Bin Lu · Fifth Affiliated Hospital, Sun Yat-Sen University
+25 more
· First Affiliated Hospital of Guangxi Medical University · First Affiliated Hospital of Wannan Medical College · Jiangsu Hengrui Pharmaceutical Co., Ltd. · Northern Jiangsu People's Hospital · Qian geng · Qianfoshan Hospital · RenJi Hospital · Second Affiliated Hospital, School of Medicine, Zhejiang University · Shandong Provincial Hospital · Shanghai East Hospital · Shanxi Provincial People's Hospital · Sir Run Run Shaw Hospital · The Affiliated Hospital of Xuzhou Medical University · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · The First Affiliated Hospital of Air Force Medicial University · The First Affiliated Hospital of Soochow University · The First People's Hospital of Changzhou · The First People's Hospital of Lianyungang · The Second Affiliated Hospital of Shandong First Medical University · The Second Hospital of Nanjing Medical University · The fourth affiliated hospital of nantong university · Wuxi People's Hospital · Xiqiao Zhou · Zhejiang Provincial People's Hospital · Zhongnan Hospital

Trials 31

today NCT07687212 · Ph 1/2 NCT07294495 · not/applicable NCT07323381 · Ph 4 NCT07027774 · Ph 4 NCT06888050 · Ph 4 NCT06762223 · Ph 4 NCT06448130 · Ph 4 NCT06085703 · not/applicable NCT06218342 · Ph 4 NCT06216340 · Ph 4 NCT06031389 · not/applicable NCT06059287 · not/applicable NCT06187727 · Ph 4 NCT05742230 · not/applicable NCT05677334 · Ph 4 NCT05682495 · Ph 1 NCT05692934 · Ph 1 NCT05120219 · Ph 1 NCT06083116 · Ph 1 NCT03329118 · Ph 1 NCT04390295 · Ph 3 NCT03159052 · Ph 3 NCT03160014 · Ph 1 NCT02500485 · Ph 1 NCT02366377 · Ph 1 NCT02366351 · Ph 1 NCT02354027 · Ph 1 NCT02346175 · Ph 1 NCT02353975 · Ph 1 NCT02361138 · Ph 1 NCT02356224 · Ph 1

20132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 114 trials
Phase 1	NCT05682495	Jan → Apr 2023	type 2 diabetes mellitus	Shandong Suncadia Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT05692934	Jan → Mar 2023	type 2 diabetes mellitus	Shandong Suncadia Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT05120219	Oct → Nov 2021	type 2 diabetes mellitus	Shandong Suncadia Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT06083116	Aug → Oct 2019	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT03329118	Nov → Dec 2017	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT03160014	Jun 2015 → Dec 2017	—	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT02500485	May → Jul 2015	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT02366377	Feb 2015 → Mar 2016	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT02366351	Feb 2015 → Jan 2016	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 1	NCT02354027	Sep → Nov 2014	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02346175	Jun → Sep 2014	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02353975	May → Jul 2014	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02361138	Dec 2013 → May 2014	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT02356224	Jun → Dec 2013	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded

Phase 1/21 trial
Phase 1/2	NCT07687212	Jul 2026 → Sep 2027 expected	heart failure	The First Affiliated Hospital of Air Force Medicial University	Not yet recruiting	No outcome recorded
Phase 32 trials
Phase 3	NCT04390295	Nov 2017 → May 2020	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT03159052	Jun 2017 → Oct 2018	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 49 trials · 1 met primary
Phase 4	NCT07323381	Dec 2025 → Sep 2027 expected	type 2 diabetes mellitus	Bin Lu	Not yet recruiting	No outcome recorded
Phase 4	NCT07027774	Jul 2025 → Dec 2027 expected	chronic kidney disease	First Affiliated Hospital of Wannan Medical College	Not yet recruiting	No outcome recorded
Phase 4	NCT06888050	Apr 2025 → Jun 2026 overdue	type 2 diabetes mellitus	Zhejiang Provincial People's Hospital	Recruiting	No outcome recorded
Phase 4	NCT06762223	Dec 2024 → Dec 2026 expected	metabolic dysfunction-associated steatotic liver disease, type 2 diabetes mellitus	Xiqiao Zhou	Not yet recruiting	No outcome recorded
Phase 4	NCT06448130	Jun 2024 → Dec 2026 expected	prediabetes syndrome, type 2 diabetes mellitus	Shandong Provincial Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT06218342	Feb 2024 → Dec 2025	NAFLD1, type 2 diabetes mellitus	Sir Run Run Shaw Hospital	Unknown	No outcome recorded
Phase 4	NCT06216340	Feb 2024 → Oct 2026 expected	obesity disorder, prediabetes syndrome	The First People's Hospital of Changzhou	Not yet recruiting	No outcome recorded
Phase 4	NCT06187727	Jul 2023 → Jan 2025	heart failure, myocardial infarction	Qian geng	Completed	No outcome recorded
Phase 4	NCT05677334	Mar 2023 → Oct 2024	type 2 diabetes mellitus	First Affiliated Hospital of Guangxi Medical University	Completed	Met primary
Phase not applicable5 trials · 1 met primary
—	NCT07294495	Jan 2026 → Dec 2028 expected	hypertrophic cardiomyopathy	Shanghai East Hospital	Not yet recruiting	No outcome recorded
—	NCT06085703	Apr 2024 → Jun 2025	cognitive impairment with or without cerebellar ataxia, type 2 diabetes mellitus	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	Completed	Met primary
—	NCT06031389	Jan → Dec 2024	diabetic kidney disease	Qianfoshan Hospital	Unknown	No outcome recorded
—	NCT06059287	Oct 2023 → Dec 2025	obesity disorder, type 2 diabetes mellitus	RenJi Hospital	Unknown	No outcome recorded
—	NCT05742230	Apr 2023 → Jul 2024	heart failure	Second Affiliated Hospital, School of Medicine, Zhejiang University	Unknown	No outcome recorded
Comparator or background therapy2 trials
Phase 1	NCT03159832 Comparator	Jun 2015 → Dec 2017	kidney failure	Jiangsu HengRui Medicine Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT05252624 Comparator	Sep 2022 → Sep 2023	atrial fibrillation	Beijing Anzhen Hospital	Unknown	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2026-08-10	Jiangsu HengRui Medicine Co., Ltd.	Results 恒瑞创新药恒格列净针对T2DM合并高血压患者心脏研究成果发表于Cardiovascular Diabetology hengrui.com ↗ 在标准治疗的基础上，联用恒格列净6个月可显著减轻T2DM合并高血压患者的心室重构，并改善左室舒张功能，同时实现9.45 mmHg的血压下降及体重和血糖控制的多重改善。

All press releases naming this drug 1 release

Date	Issuer	Release
2026-08-10	Jiangsu HengRui Medicine Co., Ltd.	恒瑞创新药恒格列净针对T2DM合并高血压患者心脏研究成果发表于Cardiovascular Diabetology hengrui.com ↗

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 34 sources stand behind the page.

Field	Value	Cited text
Known as	Henagliflozin	“Primary anti-HF therapy + Henagliflozin Proline Tablets (10mg, 1 times/day) + clostridial enterococcus triple live tablet (400mg, 3 times/day) orally, for 12 weeks.” NCT07687212 ↗ 16 NCT06448130 ↗ NCT06187727 ↗ NCT06216340 ↗ NCT06762223 ↗ NCT06031389 ↗ NCT07323381 ↗ NCT05742230 ↗ NCT07027774 ↗ NCT06083116 ↗ NCT05677334 ↗ Show 6 more sources
Known as	SHR3824	“Henagliflozin (SHR3824) is a hypoglycemic agent classified as an SGLT2i, which has been independently developed by Jiangsu Hengrui Pharmaceutical Co., Ltd. (China) and Shanghai...” NCT06762223 ↗ 16 “The purpose of this study is to assess the effect of food on the single-dose PK of SHR3824, SP2086 and metformin in the HR20031 FDC tablets in healthy subjects.” NCT05692934 ↗ “Subjects will receive treatment SHR3824 10 mg+ SP2086 100 mg+ Metformin 500 mg XR\*2 followed by 7 days washout” NCT05682495 ↗ “single-dose PK of SHR3824 and metformin administered in the HR20033 FDC tablet” NCT05120219 ↗ NCT02366377 ↗ NCT02353975 ↗ NCT03160014 ↗ NCT03159832 ↗ NCT03159052 ↗ NCT03329118 ↗ NCT02354027 ↗ Show 6 more sources
Action	Inhibit	“SHR3824(a Sodium-Glucose Cotransporter 2 inhibitor)” NCT02354027 ↗ 1 “Sodium/glucose cotransporter 2 inhibitor” CHEMBL4297431 ↗
Modality	Small molecule	— CHEMBL4297431 ↗
Route	Oral	“single and multiple oral doses of 5mg to 20 mg SHR3824 in Type 2 diabetes mellitus patients.” NCT02346175 ↗
Target	SLC5A2	“Sodium/glucose cotransporter 2 inhibitor” CHEMBL4297431 ↗